Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.

Abstract

BACKGROUND The development of neutralizing alloantibodies (inhibitors) is the most serious complication of factor VIII (FVIII) replacement therapy in patients with hemophilia A. Unlike previously untreated patients, no definite risk factors for inhibitor development are known for previously treated patients (PTPs). The investigation of the development of… (More)
DOI: 10.1111/jth.12335

Topics

  • Presentations referencing similar topics